The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program

Autor: Monika Joks, Renata Kasza, Janusz Kloczko, Edyta Paczkowska, R. Kroll-Balcerzak, Elżbieta Patkowska, Olga Grzybowska-Izydorczyk, Monika Biernat, Ryszard Wichary, Wioletta Makowska, Joanna Gora-Tybor, Tomasz Sacha, Malgorzata Wach, Małgorzata Kopera, Marta Oller, Aleksandra Kostyra, Hanna Ciepluch, Joanna Niesiobedzka-Krezel, Joanna Wasilewska, Anna Rudkowska-Kazanowska, Magdalena Swiniarska, Grazyna Bober, Paulina Dumnicka, Witold Prejzner, Ewa Wasilewska, Tomasz Gromek, Elżbieta Szczepanek, Justyna Gil

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:405-415

Introduction: Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML. This study aimed to evaluate the effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd3212de4c1c567c7d12ec8ee815f7f
https://doi.org/10.1016/j.clml.2021.11.012

Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group

Autor: Ewa Wasilewska, Grazyna Bober, Katarzyna Kapelko-Słowik, Waldemar Sawicki, Joanna Drozd-Sokołowska, Krzysztof Mądry, Rafał Machowicz, Agnieszka Piekarska, Jadwiga Dwilewicz-Trojaczek, Krzysztof Lewandowski, Katarzyna Budziszewska, Helena Krzemień, Paweł Szwedyk, Agata Obara, Przemyslaw Biecek, Magdalena Raźny, Anna Waszczuk-Gajda, Małgorzata Paszkowska-Kowalewska, Magdalena Dutka, Beata Stella-Holowiecka

Publikováno v: Hematological Oncology. 36:570-575

Atypical chronic myeloid leukaemia (aCML) belongs to myelodysplastic/myeloproliferative neoplasms. Because of its rarity and changing diagnostic criteria throughout subsequent classifications, data on aCML are very scarce. Therefore, we at the Polish

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63be164810529ebc853f7c7d749e2f1e
https://doi.org/10.1002/hon.2501

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy : a Multicenter Prospective Observational Study

Autor: Andrzej Hellmann, Tomasz Sacha, Joanna Wącław, Ewa Mędraś, Slawomira Kyrcz-Krzemien, Ewa Wąsak-Szulkowska, Rafał Becht, Joanna Góra-Tybor, Grazyna Bober, Aneta Kotowska

The aim of this study was to evaluate quality of life (QOL) and adherence to the therapy in patients with chronic myeloid leukemia in chronic phase treated with nilotinib as second-line therapy.A multicenter, prospective, observational trial with 6 t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea818bb54e3b4cd22ba594ede042933
https://ruj.uj.edu.pl/xmlui/handle/item/140047

Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience

Autor: Grazyna Bober, Slawomira Kyrcz-Krzemien, Tomasz Oleksy, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Grzegorz Helbig, Lech Sedlak

Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases
Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015003-e2015003 (2015)

Introduction Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. Due to prolonged administration of IM, the questions about t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f142da1fcbc3904084949fa232ecc0
http://europepmc.org/articles/PMC4283924

[A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up]

Autor: Jerzy, Hołowiecki, Lech, Konopka, Grazyna, Bober, Sebastian, Giebel, Bernadeta, Ceglarek, Kinga, Kos, Beata, Stella-Hołowiecka, Tomasz, Kruzel, Małgorzata, Kopera, Aleksandra, Bartkowska-Chrobok, Ewa, Pszenna, Anna, Sikorska, Barbara, Pieńikowska-Grela

Publikováno v: Polskie Archiwum Medycyny Wewnetrznej. 115(6)

Targeted therapy with the use of imatinib mesylate is a recognized option for patients with chronic myeloid leukemia (CML) not eligible for allogeneic hematopoietic cell transplantation. We present results of a multicenter phase II study on the use o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d65c57e7144881e8e32a01148345f678
https://pubmed.ncbi.nlm.nih.gov/17263225